Development of COVID-19 Vaccine Policy - United States, 2020-2023
Overview
Authors
Affiliations
COVID-19 vaccines represent a great scientific and public health achievement in the face of overwhelming pressures from a global pandemic, preventing millions of hospitalizations and deaths due to COVID-19 vaccines in the United States. Over 675 million doses of COVID-19 vaccines have been administered in the United States, and over 80% of the U.S. population has had at least 1 dose of a COVID-19 vaccine. Over the course of the COVID-19 pandemic in the United States, over one million people died from COVID-19, and over six million were hospitalized. It has been estimated that COVID-19 vaccines prevented more than 18 million additional hospitalizations and more than 3 million additional deaths due to COVID-19 in the United States. From the beginning of the COVID-19 pandemic in 2020 through June 2023, ACIP had 35 COVID-19 focused meetings and 24 votes for COVID-19 vaccine recommendations. ACIP had the critical task of rapidly and thoroughly reviewing emerging and evolving data on COVID-19 epidemiology and vaccines, as well as making comprehensive population-based recommendations for vaccine policy and considerations for implementation through a transparent and evidence-based framework. Safe and effective COVID-19 vaccines, recommended through transparent policy discussions with ACIP, remain the best tool we have to prevent serious illness, hospitalization and death from COVID-19.
El Kalach R, Jones-Jack N, Grabenstein J, Elam M, Olorukooba A, deMartino A J Am Pharm Assoc (2003). 2024; 65(1):102305.
PMID: 39615591 PMC: 11839327. DOI: 10.1016/j.japh.2024.102305.
Markowitz L, Hopkins Jr R, Broder K, Lee G, Edwards K, Daley M Vaccine. 2024; 42 Suppl 3:125549.
PMID: 38341293 PMC: 11310362. DOI: 10.1016/j.vaccine.2023.12.059.
Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
Link-Gelles R, Britton A, Fleming-Dutra K Vaccine. 2023; 42 Suppl 3:125492.
PMID: 38129285 PMC: 11304400. DOI: 10.1016/j.vaccine.2023.12.002.